Nanjing Hicin Soars 7.27%, Hits Intraday High of CNY 42.97

Nanjing Hicin Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.27% on June 18, 2026. The stock reached an intraday high of CNY 42.97, marking a notable achievement for the small-cap company in the Pharmaceuticals & Biotechnology sector. In comparison to the broader market, represented by the China Shanghai Composite, which saw a decline of 0.43% on the same day, Nanjing Hicin's performance stands out. Over the past week, the stock has surged by 35.45%, while its monthly performance reflects a 9.19% increase. However, the company has faced challenges over the longer term, with a year-to-date performance of -18.36% and a one-year return of -1.67%, significantly lagging behind the market's 20.71% gain. Despite these fluctuations, Nanjing Hicin reported positive results in its latest financial disclosures, with net sales growing by 25.6% and net profit increasing by 55.88%. The company maintains a low debt-equity ratio of 0.21, indicating a conservative approach to leverage. As it navigates the competitive landscape, Nanjing Hicin's recent stock activity reflects its ongoing efforts to enhance its market position.